Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation

Karam Khaddour; Joshua Dowling; Jiayi Huang; Martha Council; David Chen; Lynn Cornelius; Tanner Johanns; Sonika Dahiya; George Ansstas

doi:10.18632/oncotarget.28365

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation

PDF | How to cite

Oncotarget. 2023; 14:126-126. https://doi.org/10.18632/oncotarget.28365

Metrics: PDF 835 views | ?

Karam Khaddour¹, Joshua Dowling², Jiayi Huang³, Martha Council⁴, David Chen⁴, Lynn Cornelius⁴, Tanner Johanns¹, Sonika Dahiya⁵ and George Ansstas¹

¹Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA
²Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
³Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA
⁴Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri, USA
⁵Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

Published: February 11, 2023

Copyright: © 2023 Khaddour et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Informed patient consent was obtained.

Original article: Oncotarget. 2020; 11:4836–4844. DOI: https://doi.org/10.18632/oncotarget.27848

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28365

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation